Overview FOG-001 in Locally Advanced or Metastatic Solid Tumors Status: Recruiting Trial end date: 2027-08-31 Target enrollment: Participant gender: Summary The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer. Phase: Phase 1/Phase 2 Details Lead Sponsor: Fog Pharmaceuticals, Inc.